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INTRODUCTION
Schizophrenia is a severe mental illness that constitutes a 
prototype of psychiatric disorders, although its aetiopathogenic 
basis is not entirely known. According to epidemiological 
studies, its prevalence fluctuates between 0.5% and 1.0% in 
the population.(1) The World Health Organization classifies this 
illness as among the top ten disorders causing a greater disability 
in the adult population.(2)
 During the last 60 years and following the introduction of 
chlorpromazine into clinical practice, the mainstay treatment 
of schizophrenia has been based on the use of antipsychotic 
drugs.(3) The first drugs, termed ‘first-generation drugs’ (i.e. 
classical or typical drugs), showed great efficacy in reducing 
positive symptoms (e.g. hallucinations and delusions); however, 
a main limitation of these drugs was the onset of extrapyramidal 
side effects (EPS). The reintroduction of clozapine in the United 
States – a neuroleptic commercialised in the 1960s that was 
later withdrawn due to its ability to induce agranulocytosis(4) – 
brought a dramatic change in research expectations. This 
agent, apart from causing few EPS, showed clinical efficacy in 
improving both positive and negative symptoms in patients 
who were refractory to other first-generation antipsychotic 
drugs.(5) The reintroduction of clozapine, together with the 
introduction of risperidone in 1993,(4) opened the door to ‘atypical 
antipsychotics’,(6) also known as second-generation antipsychotic 
drugs (SGAs).
 The advances achieved in the field of antipsychotic drugs 
in the past 30 years have been incredibly important, leading 
to the clinical introduction of numerous SGAs (Table I). 
These agents have notably improved the quality of life of 
psychotic patients and contributed toward reducing the stigma 
associated with such a crippling disease.(7) Following the clinical 
introduction of new antipsychotics in 1993 and the subsequent 
authorisation of their use for the treatment of bipolar disorder 
in 2003, research efforts related to these drugs saw a manifold 
increase.(8) We hypothesised that this increase in research 
would have correlated with an increase in the volume of 
published scientific literature on these drugs and thus 
proceeded to analyse published scientific literature on SGAs in 
Singapore.
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INTRODUCTION A bibliometric study was carried out to ascertain the volume and impact of scientific literature 
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Singapore that included the descriptors ‘atypic* antipsychotic*’, ‘second-generation antipsychotic*’, ‘clozapine’, 
‘risperidone’, ‘olanzapine’, ‘ziprasidone’, ‘quetiapine’, ‘sertindole’, ‘aripiprazole’, ‘paliperidone’, ‘amisulpride’, ‘zotepine’, 
‘asenapine’, ‘iloperidone’, ‘lurasidone’, ‘perospirone’ and ‘blonanserin’ in the article titles. Certain bibliometric indicators 
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non-fulfilment of Price’s Law (r = 0.0648 after exponential adjustment vs. r = 0.2140 after linear adjustment). 
The most widely studied drugs were clozapine (21 articles), risperidone (16 articles) and olanzapine (8 articles).  
Division into Bradford zones yielded a nucleus occupied by the Journal of Clinical Psychopharmacology  
(6 articles) and the Singapore Medical Journal (4 articles). The analysed material was published in a total of 30  
journals, with the majority from six journals. Four of these six journals have an impact factor greater than 2.
CONClUsION Publications on SGAs in Singapore are still too few to confirm an exponential growth of scientific 
literature.
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 Although Singapore is an emergent country with a highly 
developed, market-based economy, it has a short psychiatric 
history. A substantial proportion of people in Singapore rely on 
a mixture of Western and traditional medicines, and seek help 
from spiritual healers or practitioners of traditional medicine; in 
some instances, this results in delayed psychiatric treatment.(9) 
There are about 115 practising psychiatrists in Singapore, giving 
a psychiatrist-to-population ratio of 2.6/100,000, which is low 
compared to other developed countries such as the United 
States of America (USA), which has a psychiatrist-to-population 
ratio of 13.7/100,000.(10) However, the Ministry of Health in 
Singapore has supported the local development of the field 
of psychiatry and the use of evidence-based practice guide- 
lines; it has also published clinical practice guidelines on 
schizophrenia(10) and bipolar disorder(11) to provide doctors and 
patients in Singapore with evidence-based guidance on the 
management of these disorders.
 Bibliometric studies are useful tools for assessing the social 
and scientific relevance of a given discipline or field, and may 
be of particular interest to different health professionals such as 
policy makers, researchers and clinicians.(12) In recent years, our 
group has, using a bibliometric approach, studied the evolution 
of scientific literature in psychiatry pertaining to the different 
aspects of different psychiatric disorders and the specific 
therapeutic modalities being pursued within the field of 
psychopharmacology.(8,13-17) In the present study, we had the 
specific aim of conducting a bibliometric assessment of the 
scientific literature published on SGAs in Singapore from 1997 
to 2011.
MeThODs
Both the MEDLINE (Index Medicus, US National Library of 
Medicine, Bethesda, Maryland, USA) and Excerpta Medica 
(Elsevier Science Publishers, Amsterdam, Netherlands) databases 
were used in this bibliometric study. These two databases are 
considered to be the most exhaustive databases in the biomedical 
field, with participation in the EMBASE Biomedical Answer web 
(Elsevier BV, Amsterdam, Netherlands).
 Using remote downloading techniques, articles published 
from 1997 to 2011 containing the descriptor ‘Singapore’ in the 
AD (i.e. address of authors) field and the descriptors ‘atypic* 
antipsychotic*’, ‘second-generation antipsychotic*’, ‘clozapine’, 
‘risperidone’, ‘olanzapine’, ‘ziprasidone’, ‘quetiapine’, ‘sertindole’, 
‘aripiprazole’, ‘paliperidone’, ‘amisulpride’, ‘zotepine’, ‘asenapine’, 
‘iloperidone’, ‘lurasidone’, ‘perospirone’ and ‘blonanserin’ in the 
TI (i.e. title) field were retrieved. All articles on antipsychotic 
drugs (typical and atypical) published in Singapore during this 
period were also included. For the purpose of this study, all 
publications (original articles, brief articles, reviews, editorials 
or letters to the editor) were considered. Duplicated articles 
were omitted. The papers were categorised into four groups 
(‘experimental pharmacology’, ‘clinical efficacy’, ‘tolerance 
and/or safety’ and ‘not specified’) using manual coding after a 
brief study of the titles and/or abstracts of the articles. 
 This study, which was based entirely on an analysis of 
secondary published materials, was approved by the Research 
Ethics Committee (Comité de Ética de la Investigación) of 
Camilo José Cela University, Madrid, Spain, and conformed 
to the provisions of the Declaration of Helsinki (Edinburgh 
revision, 2000).
 Price’s Law was among the bibliometric indicators of 
production applied.(18) Price’s Law reflects exponential growth, 
which is a fundamental aspect of scientific productivity. To 
assess whether the growth of scientific publications on SGAs 
Table I. Clinical development of second-generation antipsychotic drugs. 
Drug Company name Year Country of launch
Clozapine Wander Laboratories 1972* Switzerland
Zotepine Fujisawa 1982† Japan
Amisulpride Synthelabo 1986 Portugal
Risperidone Johnson & Johnson 1993 UK/Canada
Sertindole Abbott Laboratories 1996‡ UK
Olanzapine Eli Lilly 1996 USA/UK
Quetiapine AstraZeneca 1997 USA/UK
Ziprasidone Pfizer 2001 USA
Perospirone Dainippon Sumitomo Pharma 2001 Japan
Aripiprazole Otsuka/Bristol-Myers Squibb 2002 USA
Paliperidone Janssen Pharmaceutica 2007 USA
Blonanserin Dainippon Sumitomo Pharma 2008 Japan
Asenapine Schering-Plough 2009 USA
Iloperidone Novartis AG 2009 USA
Lurasidone Dainippon Sumitomo Pharma 2011 USA
*Reintroduced in 1990 in USA and UK after being withdrawn from the market in 1975. †Commercialised by Astellas in Germany in 1990. ‡Marketing authorisation 
was suspended by the European Medicines Agency (EMA) in 1998 and the drug was withdrawn from the market. In 2002, based on new data, the EMA suggested 
that sertindole could be reintroduced for restricted use and with extensive electrocardiography monitoring. UK: United Kingdom; USA: United States of America
[Sources: PharmaProjects, PJB Publications Ltd, 2012; R&D Insight, ADIS International, 2012; International Marketing Services Health, 2012] 
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in Singapore was in agreement with Price’s Law of exponential 
growth, linear and exponential adjustments were made to the 
data obtained, using the following equations:
Similar adjustments were also made for total publications on 
antipsychotic drugs (typical and atypical) in Singapore. The 
following equations were used:
 Bradford’s Law was used as a bibliometric indicator of the 
dispersion of scientific information. With the aim of revealing 
the distribution of scientific literature in a particular discipline, 
Bradford proposed a model of concentric zones of productivity 
(termed as Bradford zones) with decreasing densities of 
information.(19) Each of these zones would contain a similar 
number of articles, but with the number of journals in which 
these articles are published increasing as one passes from one 
zone to another. The model permits the identification of journals 
that are most widely used or have the greatest weightage in a 
given field of scientific production.
 Impact factor (IF) was used as an indicator of the weight 
of the journal. The IF was developed as an indicator by the 
Institute for Scientific Information (Philadelphia, PA, USA), 
and it is published annually under the Journal Citation Reports 
(JCR) section of the Science Citation Index (SCI). The IF of a 
journal is calculated based on the number of times a journal has 
been cited in the source journals of the SCI during the previous 
two years, as well as the total number of articles published by 
the journal in question during the two-year period. The IF data 
for 2010, which was published in the 2011 JCR, (Journal Citation 
Reports, Thomson Reuters, 2011) was used in the present study. 
 The index of collaboration between authors (i.e. signatures/
document or authors/paper index) was also applied. This index 
shows the quotient between the number of authors and the total 
number of articles collected in the database. Another indicator 
included in our analysis was the national participation index (PI) 
of Singapore for overall scientific publication (i.e. the ratio of the 
number of articles generated by Singapore to the total number 
of articles on the topic). The PI of Singapore was compared with 
the global PI for biomedicine and health sciences, particularly 
the global PI for the areas of psychiatry and neurology. The PI 
was also correlated with the corresponding PIs of the world’s 
ten most productive countries, in terms of scientific literature, 
during the years 1997–2011. Other comparisons included a 
correlation of the PI with health data such as total per capita 
expenditure on health and gross domestic expenditure on 
research and development (R&D). Relevant health data were 
sourced from the publications of the Organisation of Economic 
and Co-operative Development Health Division(20) and the 
World Health Organization’s Department of Health Statistics 
and Informatics.(21)
ResUlTs
From 1997 to 2011, we retrieved 51 articles from Singapore that 
dealt with various aspects of SGAs (21 on clozapine; 16 on 
risperidone; 8 on olanzapine; 4 on asenapine; 2 on quetiapine; 
1 on paliperidone; 1 on sertindole), and 89 articles related to 
total antipsychotic drugs. No article on ziprasidone, aripiprazole, 
amisulpride, zotepine, iloperidone, lurasidone, perospirone or 
Linear adjustment: y = 0.125x – 2.4 (r2 = 0.0458)
Exponential adjustment: y = 2.4835e0.0102x (r2 = 0.0042)
Linear adjustment: y = 0.2607x – 3.8476 (r2 = 0.1432)
Exponential adjustment: y = 3.8528e0.04x (r2 = 0.1338)
Fig. 1 Radar char t shows the annual number of ar ticles published on second-generation antipsychotic 
drugs in Singapore from 1997 to 2011 with respect to the points of international authorisation of the 
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blonanserin was found. It should be noted that perospirone 
and blonanserin are not available in Singapore.
 There has only been a slight increase in the number of 
publications on SGAs generated in Singapore over the last 
15 years (Fig. 1). Mathematical adjustments to the exponential 
and linear curves confirmed that the increase in the literature 
for both SGAs and total antipsychotic drugs did not conform 
to the postulates of Price’s Law, possibly due to the small 
sample of publications (Fig. 2). The relative five-year growth of 
publications on SGAs and total antipsychotics in Singapore 
during the period studied, with the 2007–2011 interval taken 
as reference, is shown in Fig. 3. The cumulative growth in the 
literature was lower than the overall global growth of scientific 
output in the field of biomedicine and health sciences, and 
slightly less in the specific field of psychiatry and neurology 
within Singapore.
 Table II shows the results of the application of Bradford’s 
model to the scientific journals in which articles on SGAs were 
Fig. 2 Graph shows the growth of scientif ic l iterature on second-generation antipsychotic 
drugs (SGAs; solid l ine) and total antipsychotic drugs (dashed line) in Singapore. Linear 
and exponentia l adjustments were applied for the data on ar t ic les regarding SGAs and 
total antipsychotic drugs. In both cases, there was no compliance with Pr ice’s Law.(18) 
Linear adjustment (SGAs): y = 0.125x – 2.4 (r2 = 0.0458); exponential adjustment (SGAs): 
y = 2.4835e0.0102x (r2 = 0.0042); linear adjustment (total antipsychotics): y = 0.2607x – 3.8476 


















































Fig. 3 Graph shows the f ive -year cumulative growth of scientif ic literature in Singapore with 
respect to total productivity in the f ields of biomedicine and health sciences, psychiatr y 
and neurology, and second-generation antipsychotic drugs (SGAs). Data in each f ive -year 
inter val refers to evolution over the previous period. Note: The period of reference was 
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published. The mean number of articles per Bradford zone, 
when the last zone (which had a lower accuracy) was not taken 
into account, was 10. The nucleus (i.e. the first zone) included 
the Journal of Clinical Psychopharmacology (6 articles) and 
Singapore Medical Journal (4 articles). The remaining journals 
that were analysed were included in zones 2–6. The analysed 
material was found to have been published in a total of 30 
different journals. However, six journals accounted for 47.06% 
of all articles retrieved on our searches (Table III), and the 
journals most extensively used for the dissemination of research 
on SGAs had reasonably high IFs, with four journals having 
IF > 2.
 On manual classification, 37.26% of the articles retrieved 
were found to belong to the clinical efficacy group, 31.37% to 
the tolerance and/or safety group, 19.62% to the experimental 
pharmacology group and 11.65% to the not specified group 
(which mainly included reviews of different SGAs and articles 
on prescribing patterns). Clinical studies were mostly on 
schizophrenia (n = 12), with two on bipolar disorder. The 
collaboration index (i.e. quotient of studies with ‘n’ signatories), 
which is indicative of the cooperation between authors during 
article production, was 4.54 authors/article and it was found 
to have increased during the study years by 13.66% (from 4.44 
during the 1997–2001 five-year period to 5.04 during the 
2007–2011 five-year period). 
 The general publication output on SGAs from Singapore 
(PI = 0.32) was low when compared to the worldwide 
publication output during the period analysed. Table IV shows 
how Singapore compares with the top ten most productive 
countries in the fields of biomedicine and health sciences, and 
psychiatry and neurology. USA (PI = 31.63), followed by the 
United Kingdom (UK), Germany, Canada, Italy and Spain were 
the six most productive countries in terms of publication output 
on SGAs. However, when the productivity of these countries 
on SGAs was assessed in relation to their overall productivity in 
the field of psychiatry and neurology, only Spain was found to 
have a higher percentage of research on SGAs (Fig. 4). Singapore 
occupied the third position in this ranking. The distribution 
obtained from the analysis of the correlation between PI and 
the per capita health expenditure of each of the aforementioned 
countries is shown in Fig. 5.
 The most productive institutions in Singapore in relation to 
the material under study were the Institute of Mental Health 
of Woodbridge Hospital (n = 24) and the National University 
of Singapore (n = 7), both accounting for 60.78% of the total 
production of literature on SGAs in Singapore. However, 
all inferences regarding the most productive institutions in 
Singapore were drawn solely based on the information 
available in the AD field in the EMBASE Biomedical Answer 
web database.
DIsCUssION
Bibliometric studies constitute interesting tools for assessing 
the social and scientific importance of a given discipline over a 
specific period of time. Despite their methodological limitations, 
these studies permit an overview of the growth, size and 
distribution of scientific literature related to a particular discipline, 
as well as the study of the evolution of not only the biomedical 
speciality, field of specialisation or issue in question, but also the 
scientific production of an institution, country, author or research 
group. Previous bibliometric studies have drawn attention to a 
series of limitations characteristic of this sociometric approach.(22) 
For example, international scientific production in any particular 
field (e.g. SGAs, as is the case in the present study) is much 
more extensive than what is indexed in the usual databases (i.e. 
many journals or contributions made to scientific conferences 
and meetings are not indexed in such databases). Nevertheless, 
the recognised quality of the publications included in the 
databases selected for the present study and their extensive 
coverage imply that the articles retrieved from our searches 
would constitute more than a representative sample of the 
international research on the area in question. 
 Our study design allowed us to make a global assessment of 
the growth of the scientific literature on SGAs in Singapore. We 
found that the number of scientific publications on SGAs had 
only increased slightly in Singapore in recent years, with no 
evident exponential growth (correlation coefficient, r = 0.0648 
after exponential adjustment vs. r = 0.2140 after linear adjustment), 
Table II . Distribution of scientific literature on second- 
generation antipsychotic drugs in singapore in Bradford zones. 
Bradford 
zone
No. of journals 
(n = 30)





2 3 9 1.5
3 5 11 1.67
4 9 10 1.8
5 10 10 1.11
6 1 1
The mean no. of articles per Bradford zone was 8.5. The mean no. of articles 
per Bradford zone when the last Bradford zone was excluded was 10.
Table III. The top six journals with the highest number of 
articles published on second-generation antipsychotic drugs 
in singapore. 






Journal of Clinical 
Psychopharmacology
6 11.76 4.857
Singapore Medical Journal 4 7.84 0.730
Annals of the Academy 
of Medicine Singapore
3 5.88 1.203
Australian and New Zealand 
Journal of Psychiatry
3 5.88 2.418






*Data extracted from Journal Citation Reports, Thomson Reuters, 2011.
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mirroring patterns reported earlier for other emergent East Asian 
countries such as Taiwan and South Korea.(16,17) Our inferences 
showed a close correlation with the prescription data reported 
in recent pharmacoepidemiological studies by the Research on 
Asian Psychotropic Prescription (REAP) project for countries 
in this region (e.g. China, Hong Kong, Japan, Korea, Singapore 
and Taiwan).(23,24) According to Nakano et al, the prescribing 
patterns for SGAs showed a significant increase in the years 
2001 (45.5%), 2004 (64.7%) and 2008 (76.6%).(23) However, 
in Singapore, Xiang et al reported that the corresponding 
increase was slower (2001, 6.7%; 2004, 16.5%; 2009, 50.0%).(24) 
The findings of these authors show a strong correlation with 
the results of the present study, as our analysis suggested 
that research on SGAs had grown in Singapore, although not 
exponentially.
 The vast development seen in the scientific literature on SGAs 
has largely coincided with their approval for marketing by the 
US Food and Drug Administration (FDA) and other international 
regulatory agencies for the treatment of bipolar disorder. Since 
2004, other SGAs such as risperidone, ziprasidone, quetiapine, 
aripiprazole and asenapine have been approved for the 
treatment of manic episodes, while olanzapine and aripiprazole 
have been approved for the prevention of relapse in patients 
with bipolar disorder.(25) Quetiapine is indicated as monotherapy 
for the acute treatment of depressive episodes associated with 
bipolar disorder, and the olanzapine-fluoxetine combination 
Table IV. The relative publication output on second-generation antipsychotic drugs (sGAs) of singapore and the top ten most 
productive countries in biomedicine and health sciences, for the period 1997–2011.
Rank Country Articles produced during 1997–2011 (%) sGAs/Psychiatry 
& neurology
Biomedicine & health 
sciences (n = 11,678,458)




1 USA 25.85 39.71 31.63 1.03
2 UK 7.44 10.86 6.92 0.81
3 Germany 6.46 8.76 6.45 0.93
4 Japan 6.43 7.19 3.82 0.67
5 China 4.60 3.63 2.31 0.81
6 France 4.50 5.25 3.17 0.76
7 Italy 3.96 5.25 4.96 1.19
8 Canada 3.79 5.59 5.14 1.17
9 Spain 2.83 3.28 3.91 1.51
10 Australia 2.59 3.50 2.66 0.96
– Singapore 0.37 0.33 0.32 1.23
UK: United Kingdom; USA: United States of America
Fig. 4 Graph shows the relat ionship between the production of scientif ic l iterature on second-
generation antipsychotic drugs (SGAs) and total production in the f ield of psychiatr y and neurology 
in the world’s ten most productive countr ies in biomedicine and health sciences, and Singapore. 
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has been recommended for treating treatment-resistant major 
depressive disorders. In addition, aripiprazole was approved in 
2007 by FDA as an add-on to antidepressants for the treatment 
of treatment-resistant major depression.(25) SGAs are also 
commonly used, and studied, in numerous off-label indications 
for conditions such as substance-induced psychosis, agitation 
symptoms, tics and substance-abuse disorders.(26,27)
 Another aspect of interest in relation to scientific production 
that we analysed in the present study, is the quality of the 
publications. The fact that prestigious journals such as the 
Journal of Clinical Psychopharmacology (IF = 4.857) and the 
International Journal of Neuropsychopharmacology (IF = 
4.699) published articles on SGAs from Singapore indicates the 
growing relevance of research in Singapore in the recent years. 
Notably, four among the six journals in which research was most 
widely cited had a significant impact in the field of psychiatry 
(IF > 2).
 As we have shown in earlier studies,(16,17) scientific research 
on antipsychotic drugs is one of the fastest growing areas 
within the field of psychiatry. Other authors, with the use of 
bibliometric tools, have similarly reported more extensive 
research on schizophrenia than other fields of psychiatry.(28) 
According to Clement et al, the more expansive investigation on 
schizophrenia may have positive correlations with the clinical 
perception that this illness is more serious than other psychiatric 
pathologies.(28) Theander and Wetterberg reported that the 
number of citations on schizophrenia in the MEDLINE database 
(which accounted for 0.42% of the total literature published 
during the period studied) reflected the general increase in the 
number of medical publications.(29) 
 With regard to the PI of the different countries in the 
production of scientific literature on SGAs, USA and UK, two 
major English-speaking countries, head the ranking; these 
two countries generate over a third of the total scientific 
publication in the field (38.55%). The fact that these two 
countries are home to many of the major pharmaceutical 
companies responsible for the development of SGAs (e.g. Eli 
Lilly – olanzapine; Janssen Pharmaceutica – risperidone and 
paliperidone; AstraZeneca – quetiapine; Pfizer – ziprasidone; 
Bristol-Myers Squibb/Otsuka Pharmaceutical – aripiprazole) 
may explain these countries’ high PIs. In the other countries that 
appear near the top in the ranking for production of scientific 
literature on SGAs with respect to general productivity in the 
field of psychiatry and neurology (e.g. Spain, Italy and Canada), 
Fig. 5 Graph shows the per capita health expenditure and the relationship between the production of scientif ic l iterature on second-
generat ion ant ipsychotic drugs, and per capita health expenditure and gross domestic expenditure on R&D in the wor ld’s ten most 
productive countr ies in biomedicine and health sciences, and Singapore. 
Source: Data on total health expenditure per capita PPP USD from OECD 2009;(20) data on Japan and Australia from OECD 2008;(20) data 
on China and Singapore (in PPP International dollars) from WHO 2008.(21) Data on gross domestic expenditure on R&D from OECD 2010,(20) 
except for USA and Japan (data from OECD 2009),(20) China (data from OECD 2007),(20) and Singapore (data from Global Finance Magazine 
2008; http://www.gfmag.com).
OECD: Organisation for Economic Co-operation and Development; PI : par ticipation index; PPP: purchasing power parity; R&D: research 
and development; UK: United Kingdom; USA: United States of America; USD: United States dollars; WHO: World Health Organization
(PI/per capita health expenditure) × 1,000,000
UsD per capita health expenditure
PI/gross domestic expenditure on R&D
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their high ranking is a reflection of the importance given by 
these countries to research on SGAs. A similar finding can be 
observed in Singapore, where although scientific production 
on SGAs is small, it is important in the field of psychiatry and 
neurology. Chong et al(30) noted that the impact of research on 
mental health in Singapore is not evident, and that there was a 
relatively lower interest in SGAs in other East Asian countries 
such as Japan. The factors influencing the paucity of psychiatric 
research in Singapore are many, including Singapore’s low 
psychiatrist-to-population ratio (2.6 per 100,000 population), 
the shortage of other mental health professionals (e.g. 
psychiatric nurses, clinical psychologists and psychiatric case 
managers), the general perception that psychiatrists get lower 
monetary remunerations than other medical specialists, the 
inclination of psychiatric centres to cater more to clinical services, 
the larger stigma associated with mental illness in Singapore, 
as well as the continued and relatively high consumption of 
traditional medicines in the country.(9)
 The correlation of the production of scientific literature on 
SGAs with the per capita health expenditure of each country 
offered a different perspective to our findings. In general, 
there was confirmation of the perception that the higher the 
spending on health, the greater a country’s research production. 
However, it was striking to note the low ratios of countries such 
as Australia, France and Singapore. In spite of Singapore having 
the world’s third highest gross domestic product per capita 
(purchasing power parity of USD 59,936), the country had 
relatively prudent health expenditure when compared to other 
developed countries. The correlation analysis of the production 
of scientific literature on SGAs and gross domestic expenditure 
on R&D revealed that France, Australia, Japan and Singapore 
occupied the bottom four positions.
 In terms of pharmacoepidemiological observations in 
published studies, there has been an overall increase in the 
prescription of SGAs over time for the management of psychotic 
disorders such as schizophrenia in Singapore, as compared to 
the prescription of first-generation antipsychotics.(30,31) This is 
consistent with similar trends in Asia.(32) Sim et al have even 
reported the use of SGAs to be associated with the use of lower 
doses of antipsychotic drugs.(33) With regard to specific SGAs, 
data on clozapine use in Singapore showed some increase in 
prescription, and this contributed to the analyses within the 
REAP study, which associated the use of clozapine with more 
severe illness (i.e. more frequent admissions, greater severity 
of delusions, disorganisation, negative symptoms) but with 
less EPS.(34) 
 When reviewing and assimilating the results of the 
present study, it would be prudent to exercise caution against 
overinterpreting its findings in view of its inherent limitations. 
First, articles where the team of authors included authors from 
Singapore were selected for inclusion irrespective of whether 
they were based overseas or in Singapore. Such a criterion, 
however, may have led to the exclusion of articles in which the 
authors did not specify an affiliation with a specific clinical or 
academic institute in Singapore. To minimise this, we sought 
the help of various individuals familiar with relevant research 
literature from Asia and Singapore, as well as searched for relevant 
articles using various search engines, including the MEDLINE, 
EMBASE and Biomedical Answer web databases. Second, the 
use of IF as an indicator of the merit or quality of scientific 
contributions is still a matter of much debate. A low citation 
count might not necessarily mean that the article was less 
impactful – it could mean that the given topic of study is ‘not 
yet mature’ and that other studies are still ongoing. Third, only 
studies published during 1997–2011 were included in our review, 
thus excluding other efforts conducted or published prior to 
this period. Nonetheless, in spite of the present study’s many 
limitations, bibliometric studies are useful for assessing the 
social and scientific relevance of a given discipline or field. 
Bibliometric studies constitute an effective complement to the 
opinions and judgements of experts in every field, and can 
provide useful and objective data for evaluating the results of 
scientific activity, offering realistic indications of trends, as well 
as predicting how such trends might evolve over time.
 In conclusion, the present study provides a glimpse into 
the evolution of research on SGAs in Singapore vis-à-vis 
the parameters of quality and dissemination that are most 
commonly used at an international level. SGAs formed the top 
drug class in terms of market share (USD 14.6 billion per year) 
in the year 2008 in USA.(25) Given the ever-growing importance 
of this class of drugs, the fact that an ideal antipsychotic drug 
has yet to be found,(7) and the fact that the exact aetiopatho- 
genesis of schizophrenia remains to be revealed, we are of the 
opinion that research on SGAs will continue to grow in the 
coming years.
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